PTC Therapeutics director Michael Schmertzler sells $1.8m in shares

Michael Schmertzler, a director at PTC Therapeutics (NASDAQ:PTCT), sold approximately $1.8 million worth of company common stock in late August. The transactions, executed between August 26 and August 27, 2026, involved shares sold at prices ranging from $71.55 to $73.18 per share. The stock currently trades at $70.09, having delivered a strong 42% return over the past year, though it remains down 8% year-to-date.

These sales were conducted through Section Six Partners, L.P., of which Mr. Schmertzler is a general and limited partner. The transactions were pre-arranged under a Rule 10b5-1 trading plan adopted by the partnership on May 14, 2026.

On August 26, Section Six Partners, L.P. disposed of 6,874 shares at a weighted average price of $72.74, followed by an additional 5,626 shares at a weighted average price of $73.18. The following day, August 27, the partnership sold 11,890 shares at a weighted average price of $71.55, and a smaller block of 610 shares at a weighted average price of $72.22.

Following these reported transactions, Section Six Partners, L.P. indirectly holds 1,336,594 shares of PTC Therapeutics common stock. Mr. Schmertzler disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.According to InvestingPro analysis, PTCT trades near its Fair Value of $69.82, with analysts forecasting the $6 billion company will turn profitable this year despite not being profitable over the last twelve months. The platform offers access to over 10 additional ProTips and comprehensive Pro Research Reports for PTCT and 1,400+ other US stocks.

In other recent news, PTC Therapeutics reported a significant earnings beat for the second quarter of 2026, with earnings per share reaching $0.92, surpassing Wall Street’s forecast of $0.32. The company’s revenue also exceeded expectations, coming in at $361 million compared to the anticipated $293.1 million. This performance was driven by strong sales, particularly from its product Sephience, which contributed $161 million in net product revenue. As a result, PTC Therapeutics has raised its full-year revenue guidance, highlighting momentum in Sephience and international growth. The company also disclosed that it had $2.23 billion in cash at the end of the quarter, providing flexibility for future investments and potential deals. Meanwhile, global biotech funding has risen by 75% year-over-year, according to Macquarie data, indicating a robust environment for the sector. Initial public offerings in biotech have surged 224% year-over-year, with follow-on offerings increasing by 140%. Venture funding and private investments in public equity have also seen notable growth, rising 38% and 29%, respectively.